| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 06/19/2013 | CN102861084B Application of Houttuynoid D in medicine for treating ileocecum cancer |
| 06/19/2013 | CN102743759B Phosphatase-regulated supramolecular nanosphere and preparation method thereof |
| 06/19/2013 | CN102643765B Streptomyces, anti-tumor compound (Spiro-Indimycin A-D) as well as preparation method and application thereof |
| 06/19/2013 | CN102614199B Application of (4-substituted benzoyl) fluorobenzene salicylamide compound in preparation of medicine for resisting cervical cancer |
| 06/19/2013 | CN102579338B Preparation method and application of paclitaxel intravenous fat emulsion |
| 06/19/2013 | CN102579323B Paclitaxel ethosome gel and preparation method thereof |
| 06/19/2013 | CN102526077B Application of phenylacetyl fluorobenzene salicylamide compound for preparing anti-leukemia drugs |
| 06/19/2013 | CN102504227B Process method for synthesizing lactic acid-lysine copolymer by catalytically opening loop and copolymerizing with acetic bicyclo-guanidine |
| 06/19/2013 | CN102499953B Process for extracting total phenyl propanoid from paulownia bark of paulownia tomentosa (original variety) by adopting supercritical CO2 fluid technology |
| 06/19/2013 | CN102488210B Genistein hydrogel compound and its preparation method |
| 06/19/2013 | CN102423299B Preparation method for drug-loaded chitosan nano-microspheres |
| 06/19/2013 | CN102397254B 羟基喜树碱柔性脂质体及其制备方法 Hydroxycamptothecin flexible liposomes and its preparation method |
| 06/19/2013 | CN102391351B Asiatic acid modifier with anti-tumor activity and preparation method of the same |
| 06/19/2013 | CN102335269B Aromatase inhibitor |
| 06/19/2013 | CN102319254B Application of 5-iodo-sterilization nuclide to preparation of anti-tumor medicaments |
| 06/19/2013 | CN102283873B Ultrasonic extraction method for saponin of Aralia elata blade |
| 06/19/2013 | CN102267970B Phenolic compound, and preparation method and application thereof |
| 06/19/2013 | CN102267891B Novel triterpenoid compound and preparation method thereof |
| 06/19/2013 | CN102260698B PTA-linker-thanatin fusion protein expressed in escherichia coli, and anticancer research thereof |
| 06/19/2013 | CN102257138B Tumor antigen peptide and use thereof |
| 06/19/2013 | CN102250342B PEG/mPEG (Polyethylene Glycol) multi-carboxyl chemical modifying agent connected with citric acid, preparation method and application thereof in modification of toluylene compound |
| 06/19/2013 | CN102250247B Bispecific antibody to VEGF/ANG2 and application thereof |
| 06/19/2013 | CN102229598B Mapping-agathis dammara type diterpene compound, and preparation method and application thereof |
| 06/19/2013 | CN102212126B Recombinant EDI (Endothelial Genesis Inhibitor)-8t protein with endothelial cell growth inhibiting activity |
| 06/19/2013 | CN102206203B Synthesis of benzimidazole-containing naphthalimide derivatives and applications of benzimidazole-containing naphthalimide derivatives on cancer resistance |
| 06/19/2013 | CN102199587B Functional mutant of human plasminogen, its preparation method and application |
| 06/19/2013 | CN102178956B Preparation, medical application and composition of 20S-protopanaxadiol beta-cyclodextrin inclusion compound |
| 06/19/2013 | CN102133220B Preparation method of pulsatilla saponin A |
| 06/19/2013 | CN102125686B Application of hard clam polypeptide |
| 06/19/2013 | CN102099040B Pregesteron antagonists such as CDB-4124 in the treatment of breast cancer |
| 06/19/2013 | CN102070712B VEGF-A (vascular endothelial growth factor-A) protein and use thereof |
| 06/19/2013 | CN102030742B 4-(substituent phenylamino group) quinazoline derivatives used as tyrosine kinase inhibitor |
| 06/19/2013 | CN102002051B ent-6,7-open-cycle kaurene type rubescensine A derivative with anti-tumor activity and preparation method and use thereof |
| 06/19/2013 | CN101967094B Phenylacetyl quinic acid of witlooves and ester compound thereof |
| 06/19/2013 | CN101914533B Interfering rna duplex having blunt-ends and 3'-modifications |
| 06/19/2013 | CN101914168B Medical applications and preparation methods of Pleurotus ferulae Lanzi polysaccharide and composites thereof |
| 06/19/2013 | CN101914134B Linear epitope minimum motif peptide of human papilloma virus type 58 E7 protein |
| 06/19/2013 | CN101909622B Pyrrolo [1,2-C] imidazole derivates for use in the prophylaxis or treatment of cancer which is refractory to known cancer therapies |
| 06/19/2013 | CN101890042B Chinese medicinal compound preparation arsenic tetrasulfide-tanshinone-indirubin and preparation method thereof and application thereof in preparing antineoplastic agents |
| 06/19/2013 | CN101838611B Recombinant plasmodium for expressing exogenous gene and application thereof |
| 06/19/2013 | CN101827822B Crystalline indazole-derived chemotherepeutic |
| 06/19/2013 | CN101823990B Amino-acid ester dithiocarbamic acid ester compound as well as preparation method and application thereof |
| 06/19/2013 | CN101715448B Therapeutic uses of imidazol-5-carboxylic acid derivatives |
| 06/19/2013 | CN101687923B ED-A antigen of fibrinogen associated with the neovasculature of tumour metastases |
| 06/19/2013 | CN101686973B Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles |
| 06/19/2013 | CN101678214B 芳基醚哒嗪酮衍生物 Aryl ether pyridazinones |
| 06/19/2013 | CN101678082B Methods for promoting protection and regeneration of bone marrow using CXCL9 and anti-CXCL9 antibodies |
| 06/19/2013 | CN101669973B Biological immunopotentiator composition for treating cancers |
| 06/19/2013 | CN101652374B Anhydrous crystalline vinflunine salts, method of preparation and use thereof as a drug and means of vinflunine purification |
| 06/19/2013 | CN101627027B 氨基吡唑激酶抑制剂 Aminopyrazole kinase inhibitors |
| 06/19/2013 | CN101602730B Substituted imidazole derivative |
| 06/19/2013 | CN101594871B Pyrrolopyrimidine compounds and their uses |
| 06/19/2013 | CN101583605B Triazole derivative as an HSP 90 inhibitor |
| 06/19/2013 | CN101580538B WT1-origin HLA-DR-binding antigen peptide |
| 06/19/2013 | CN101550136B Diarylurea derivatives and application thereof used for preparing anti-neoplastic medicament |
| 06/19/2013 | CN101466835B Method for controlling the amount of gene product, and agent for controlling the amount of gene product |
| 06/19/2013 | CN101450939B Novel benzimidazoles compounds |
| 06/19/2013 | CN101432428B Recombinant human interferon-like proteins |
| 06/19/2013 | CN101432005B Polymer-based anti-cancer agents |
| 06/19/2013 | CN101376904B Intra-polysaccharides from mycelia of ganoderma sinensis, and preparation and use thereof |
| 06/19/2013 | CN101374509B Use of beta-hydroxy-beta-methylbutyrate to modulate the imbalance in type 1 and type 2 cytokine production |
| 06/19/2013 | CN101305990B Use of EDG receptor binding agents in cancer |
| 06/19/2013 | CN101233155B 人抗表皮生长因子受体抗体 Human anti-epidermal growth factor receptor antibody |
| 06/19/2013 | CN101072759B Triazole compounds that modulate HSP90 activity |
| 06/19/2013 | CN101040899B Antineoplastic Chinese traditional compound and the preparation and the method for producing the same |
| 06/19/2013 | CN101001869B Carcinoembryonic antigen fusions and uses thereof |
| 06/18/2013 | US8466261 Therapeutic using a bispecific antibody |
| 06/18/2013 | US8466163 Furo[2,3-d]pyrimidines and related compounds and methods for treating disease states by inhibiting tubulin polymerization |
| 06/18/2013 | US8466146 Cyclothiocarbamate derivatives as progesterone receptor modulators |
| 06/18/2013 | US8466139 Formulation |
| 06/18/2013 | US8466127 Pegylated and fatty acid grafted chitosan oligosaccharide, synthesis method and application for drug delivery system |
| 06/18/2013 | US8466111 Cyclopenta{G}quinazoline derivatives for the treatment of rheumatoid arthritis or acute myeloid leukaemia |
| 06/18/2013 | US8465762 Dermal application system for aminolevulinic acid-derivatives |
| 06/18/2013 | US8465756 Immunogenic peptides of tumor associated antigen L6 and uses thereof in cancer therapy |
| 06/18/2013 | CA2699488C Conjugates of ribosome inactivating toxins with agents that bind to er+ cell receptors |
| 06/18/2013 | CA2608496C Imidazoquinolines as lipid kinase inhibitors |
| 06/18/2013 | CA2532800C Anaplastic lymphoma kinase modulators and methods of use |
| 06/18/2013 | CA2513701C Dimerized peptide |
| 06/18/2013 | CA2468463C Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers |
| 06/18/2013 | CA2459348C Antibodies to non-functional p2x7receptor, diagnosis and treatment of cancers and other conditions |
| 06/18/2013 | CA2446087C Recombinant tumor specific antibody and use thereof |
| 06/17/2013 | CA2841173A1 Uses of labeled hsp90 inhibitors |
| 06/13/2013 | WO2013086500A1 Artificial antigen presenting cells having a defined and dynamic shape |
| 06/13/2013 | WO2013086464A1 Markers associated with chronic lymphocytic leukemia prognosis and progression |
| 06/13/2013 | WO2013086459A1 Osteopontin variants for use in suppression or prevention of tumor growth and compositions containing such osteopontin variants |
| 06/13/2013 | WO2013086451A2 Pak inhibitors for the treatment of cancer |
| 06/13/2013 | WO2013086418A1 Tumor-specifc gm-csf cytokine response as predictor of cancer vaccine effectiveness |
| 06/13/2013 | WO2013086379A2 Methods and compositions for treating antiprogestin-resistant cancers |
| 06/13/2013 | WO2013086344A1 Combination compositions and methods of treatment |
| 06/13/2013 | WO2013086308A1 Compositions and methods for treating brain cancer |
| 06/13/2013 | WO2013086228A1 Pegylated aspartyl-trna synthetase polypeptides |
| 06/13/2013 | WO2013086216A1 Improved aspartyl-trna synthetases |
| 06/13/2013 | WO2013086031A1 Method of therapy selection for patients with cancer |
| 06/13/2013 | WO2013085973A1 Treatment for angiogenic disorders |
| 06/13/2013 | WO2013085972A1 Pdgf receptor beta binding polypeptides |
| 06/13/2013 | WO2013085902A1 Combination therapy methods for treating an inflammatory breast cancer |
| 06/13/2013 | WO2013085824A1 Small molecule anti-fibrotic compounds and uses thereof |
| 06/13/2013 | WO2013085624A1 Vectors harboring toxic genes, methods and uses therefor |
| 06/13/2013 | WO2013085483A1 Targeting en2, pax2, and/or defb1 for treatment of prostate conditions |
| 06/13/2013 | WO2013085337A1 Composition for treatment or prevention of obesity, containing water extracts of perenniporia fraxinea |